Mr. Greenberg, Director of Analysis Group’s Health Care Practice, specializes in health economic analysis in complex business litigation in the biopharmaceutical and medical device industries. He has presented economic and statistical findings on cases involving alleged violations of the False Claims Act and/or Anti-Kickback Statute to investigators from US Attorney’s Offices nationwide. Mr. Greenberg has also led consulting teams in connection with class certification, liability, and damages analyses in cases involving allegations of antitrust violations, patent infringement, product failure, and product fraud. He has served as a signatory in the amicus curiae brief with the US Supreme Court in Federal Trade Commission v. Actavis Inc., et al. and has written on brand/generic and biologic/biosimilar competition as well as the use of big data and machine learning in health care litigation. In health economics and outcomes research (HEOR), Mr. Greenberg is a frequent contributor to the medical literature on the economic burden of illness and cost effectiveness of treatments, especially in the area of psychiatric disorders. He currently serves on the editorial boards of PharmacoEconomics, Journal of Medical Economics, and Expert Opinion on Pharmacotherapy. Mr. Greenberg has a master’s in economics from Western University (Canada) and an M.B.A. from the MIT Sloan School of Management.